Medicare Drug Price Controls: Round 2

Nephron’s Health Policy Team reviewed Medicare drug spending and other data to predict in a May 22nd research note the next 15 brand-name drugs that will most likely be subject Medicare drug price negotiation/setting under the Inflation Reduction Act.

For more information on this and other Nephron Research reports: